ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2349

Corticosterois Therapy Restaured Treg/Th17 Balance in Patients with Polimyalgia Rheumatica

Lorena Alvarez-Rodriguez1, Marcos Lopez-Hoyos2, Jaime Calvo-Alen3, Elena Aurrecoechea4, Teresa Ruiz Jimeno4, Ignacio Villa4, Carmen Gonzalez-Vela5 and Victor M. Martinez-Taboada1, 1Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 2Immunology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 3Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 4Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, 5Pathology Anatomy, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: corticosteroids, cytokines, polymyalgia rheumatica and regulatory cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: To characterize the levels of circulating T regulatory cells (Tregs) and Th17 cells in polymyalgia rheumatica (PMR).

Methods: The study included 46 patients with active untreated PMR and 12 age-matched healthy controls (HC). Thirty one PMR patients were also studied after disease control with corticosteroid (CS) therapy.  As disease controls, 9 patients with giant cell arteritis (GCA) and 14 with elderly onset rheumatoid arthritis (EORA) were also included.  Analysis of circulating regulatory T cells and TH17 cells were performed by flow cytometry.  The suppressive capacity of peripheral Tregs was assessed by CFSE at a 1:1/Teffector ratio after polyclonal activation with anti-CD3 and anti-CD28.

Results: The frequency of CD4+CD25hiFoxP3+CD127-/ lowCD27+ in the peripheral blood of active PMR was not significantly different from HC.  However, patients with EORA showed marginally significant lower levels than HC (p=0.048) and GCA (p=0.048) patients.  Therapy with CS showed no significant effect on the frequency of Tregs during the course of the disease.  The frequency of CD4+IL17+IFN+ and CD8+CD28–CD27+ cells was similar in all the study groups.  The frequency of Th17 cells (CD4+IL17+IFN– and CD4+IL17+CCR6+) was significantly higher in the peripheral blood of patients with PMR compared to HC (p=0.037) and decreased after disease control with CS therapy (p=0.031).  No significant differences between PMR and the other disease controls were found.  Consequently, the ratio Tregs/Th17 was significantly decreased in patients with active PMR (p=0.024) and restored to normal after disease control.  Moreover, the suppressive capacity of Tregs was slightly increase in PMR patients compared to HC (p=0.047). 

Conclusion: Active PMR is associated with increased frequency of Th17 cells that is corrected after CS therapy. The frequency of Tregs does not change in PMR.  Thus, the onset of PMR seems to be associated with increased inflammatory cells with not counterbalance by regulatory cells.

Funding: ISCIII-FIS, IFIMAV


Disclosure:

L. Alvarez-Rodriguez,
None;

M. Lopez-Hoyos,
None;

J. Calvo-Alen,
None;

E. Aurrecoechea,
None;

T. Ruiz Jimeno,
None;

I. Villa,
None;

C. Gonzalez-Vela,
None;

V. M. Martinez-Taboada,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/corticosterois-therapy-restaured-tregth17-balance-in-patients-with-polimyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology